Close to all surveyed state Medicaid officials said they're inclined to limit coverage of treatments shown to be less cost-effective than what's already on the market, and much of the time they don't consider individual patient differences, according to a survey by the National Pharmaceutical Council. During the Obamacare debate, drug and medical device makers warned that if comparative effectiveness research included cost considerations, the research could unintentionally impede work to individualize treatments and limit options for sick patients. After...